Why is Tilray stock up today?

Traders Union
All News
Financial News
Tilray rises 2.52% today to $5.06

Highlights

Tilray reported year-to-date sales of $633.7 million, mostly from Canada and Europe, but remains unprofitable with a $67.2 million loss.
The company divested its US Atwater beer brand and acquired select Brewdog UK assets while forming a new German medical cannabis partnership set for 2026.
Technically, Tilray trades below key moving averages with a bearish trend, vulnerable to renewed weakness unless it sustains above $5.30 resistance; expected to trade between $4.70 and $5.30 near-term.

Portfolio shifts and sales drag as international expansion continues

Tilray has reported year-to-date sales of $633.7 million, primarily from Canada and the European Union, but remains unprofitable with a GAAP net loss of $67.2 million. The company sold its US beer brand Atwater back to its original owner to concentrate on stronger brands and acquired select Brewdog businesses in the UK, although those assets are seeing lower sales and volumes. In addition, Tilray introduced new alcohol products in the US and formed a partnership in Germany to expand medical cannabis access across 3,600 pharmacies starting April 1, 2026.

Anton Kharitonov, expert at Traders Union, points out that Tilray’s price remains below key moving averages, a sign of broad technical weakness. He underscores the strong selling momentum, with the stock showing deep oversold readings and limited evidence of recovery in technical indicators. The analyst also draws attention to the company’s unprofitable status and strategic reshuffling, skeptical of near-term upside given the lack of supportive fundamentals or clear positive sentiment. Kharitonov notes that even moderate intraday buying is insignificant against persistent downward pressure. He concludes, "Investors should treat any rebound as fragile — there is little substance to support a lasting turnaround right now."

Viktoras Karapetjanc, expert at Traders Union, remains constructive despite the current price weakness. He views Tilray’s recent international partnerships and new product launches as long-term opportunities for growth and market leadership. Karapetjanc sees the streamlining of the brand portfolio and expansion into the German medical cannabis market as key drivers for future revenue and demand. The analyst believes broader sector shifts and regulatory developments will support recovery. He states, "Tilray’s bullish structure remains intact — market offers multiple setups for forward-looking investors."

Oversold signals dominate as volatility rises near resistance

Momentum signals for TLRY are negative, with MACD and RSI both showing sell readings and a neutral ADX indicating a lack of strong trend direction. Multiple oversold signals, including an RSI at 33.42, a Stochastic RSI at 11.63, and CCI at -166.02, reveal the stock is deeply oversold on the daily chart. Bull/Bear Power (BBP) is slightly positive at 0.13, suggesting some intraday buying activity, while the price is close to session highs following an upside gap (+$0.06), amid moderately elevated volatility of 4.91%. The key dynamic resistance is the Ichimoku Kijun line at $5.59, with technicals confirming any intraday strength remains limited against a backdrop of longer-term weakness.

Previously it was reported that Tilray faced persistent selling pressure and technical weakness, even as strategic moves such as divestitures and heightened options activity raised volatility. The latest developments reinforce a cautious outlook, with range-bound trading likely to persist unless a breakout above $5.30 or a breach below $4.70 shifts the prevailing scenario.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.